Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352631 | 0.82 | TDP1 (0.39) | TDP1TSHRCYP3A4MAPTALDH1A1 | |
| SCHEMBL9294641 | 0.82 | TDP1 (0.37) | TDP1TSHRCYP3A4MAPTALDH1A1 | |
| SCHEMBL352550 | 0.80 | TDP1 (0.40) | TDP1TSHRCYP3A4MAPTALDH1A1 | |
| SCHEMBL31217853 | 0.79 | TSHR (0.47) | TDP1TSHRCYP3A4MAPTLMNA | |
| SCHEMBL64376 | 0.79 | — | — | |
| SCHEMBL419965 | 0.78 | TDP1 (0.53) | TDP1TSHRCYP3A4MAPTLMNA | |
| SCHEMBL2258666 | 0.78 | ALDH1A1 (0.54) | TSHRMAPTLMNAALDH1A1HSD17B10 | |
| SCHEMBL468460 | 0.78 | TSHR (0.44) | TDP1TSHRCYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL22017 | 0.77 | — | — | |
| SCHEMBL1057516 | 0.77 | TSHR (0.50) | TDP1TSHRCYP3A4MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200115371-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10479783-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-RE47396-E1 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-9920041-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9611260-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150259332-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9067925-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2598500-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-8343954-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| WO-2012015972-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-3734950-A | PRODUCTION OF 3-ACETOXY-2-METHYLENE PROPIONIC ACID ALKYL ESTERS | BAYER AG | 1973-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115371-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
| US-20150259332-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
| US-10479783-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
| US-20170158683-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | TDP1 3386/4885TSHR 4061/4885CYP3A4 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.